Membranous glomerulonephritis, psoriasis and etanercept. A chance or causal association?

Authors :: Florit EA
Ubeda-Aranda I
Delgado-Conde P
Rodríguez-Cubillo B
Monzón-Vázquez T
de la Flor Merino JC
Valga-Amado F
Barrientos-Guzmán A
Source :: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia [Nefrologia] 2012; Vol. 32 (2), pp. 228-32. Date of Electronic Publication: 2012 Mar 16.
Publication Year :: 2012
Abstract: Psoriasis is a cutaneous disease with systemic involvement. Tissue damage is considered to be immune-mediated, and etanercept currently provides effective treatment. Kidney injury arising from this condition has not yet been fully explained in the literature. We present a case of membranous nephropathy with C1q deposits followed by development of psoriasis. In this article we will review the possible association between these conditions and the response to this biological molecule.

Subjects :: Adult
Etanercept
Humans
Male
Glomerulonephritis, Membranous complications
Glomerulonephritis, Membranous drug therapy
Immunoglobulin G therapeutic use
Immunosuppressive Agents therapeutic use
Psoriasis drug therapy
Psoriasis etiology
Receptors, Tumor Necrosis Factor therapeutic use

Language :: English; Spanish; Castilian
ISSN :: 1989-2284
Volume :: 32
Issue :: 2
Database :: MEDLINE
Journal :: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
Publication Type :: Academic Journal
Accession number :: 22421953
Full Text :: https://doi.org/10.3265/Nefrologia.pre2011.Nov.11112

Full Text Access

Tools